Enhertu has now been granted five Breakthrough Therapy Designations, including three in breast cancer and one in both lung and gastric cancers
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged
Giredestrant shows promise despite missing primary goal
The NDA filing is supported by results from the phase III evERA Breast Cancer study
The findings, based on an exploratory analysis, indicate that CD47 expression may predict which patients benefit most from the therapy
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
The move strengthens GBL’s clinical-stage presence in the United States
Updated results from the EMBER-3 study showed that the drug -- Inluriyo (imlunestrant) -- as a standalone treatment cut the risk of progression or death by 38%
Data show adjuvant Verzenio plus endocrine therapy extends overall survival and sustains long-term improvements in invasive disease-free survival
Subscribe To Our Newsletter & Stay Updated
